Eye drops "interpal"

 

(57) Abstract:

The invention relates to the field of medicine. Drops can be used to treat viral diseases of the cornea. The invention is characterized by the fact that eye drops containing sulfated glycosaminoglycans and saline salts of sodium, according to the invention additionally contain interferon in the following ratio of components in 1 ml: sulfated glycosaminoglycans 50-1000 μg; interferon 10000-100000 ME, physiological salt solution of sodium else. The invention provides a reduction of treatment time and reducing the number of complications associated with corneal opacity. 6 C.p. f-crystals.

The invention relates to medicine, namely to ophthalmology, and can be used for the treatment of viral diseases of the cornea.

Known eye drops "Balaban" containing sulfated glycosaminoglycans, sodium chloride, one - and disubstituted salts of sodium and water (U.S. Pat. RF 2128975), which has a specific effect on reparative processes in the cornea.

The drawback of such drops is the lack of antiviral activity. The objective of the invention is the creation of complexname cornea in viral infections of the eye.

The technical result is the reduction of treatment time and reducing the number of complications associated with corneal opacity.

The technical result is achieved in that eye drops containing sulfated glycosaminoglycans and saline salts of sodium, according to the invention additionally contain interferon in the following ratio of components in 1 ml:

Sulfated glycosaminoglycans - 50 - 1000 mcg

Interferon - 10000 - 100000 IU

Physiological salt solution sodium - Rest

One variant of the invention is one in which eye drops additionally contain carnosine in the amount of 0.05-2.0%, and/or a preservative at a concentration of from 0.005 to 0.03%, and/or the prolongator at a concentration of 0.05 to 5.0%, and as a physiological solution of sodium salts using an aqueous solution of 0.85 to 0.92% sodium chloride or isotonic solution of sodium chloride in phosphate buffer with a pH of 6.8 to 7.6, or isotonic sodium chloride solution in borate buffer with a pH of 6.8 to 7.6.

Sulfated glycosaminoglycans (sgag) are important components of connective tissues, including the cornea. To the class of sgag include keratan-sulfate, chondroitin-sulfate, heparan-sulfate, but-salt balance and promote transparent recovery of the corneal stroma.

Human leukocyte interferon is a cytokine - biologically active substances of natural origin, an important component of antiviral defense and is produced in response to viral infection. Interferon has a broad spectrum of antiviral activity and protects corneal tissue from the cytopathic effect of the virus. For use of interferon in medicines it is synthesized in the culture of donor cells in response to viral induction, then the virus is subjected to chemical inactivation, interferon concentrate and purify.

Carnosine - getidentity dipeptide found in many human tissues, including the eye. It is an antioxidant, stabilizes cell membranes, promotes their recovery from injuries, normalizes metabolic processes in the damaged tissues.

The preservative must be entered in the part of the eye drops if the volume of packing in excess of the daily requirement, to prevent the propagation of extraneous microflora in an open package you are using. As preservative use preservatives for ophthalmic drops, for example, nipagin, thiomersal, etc.

P is icalneu cavity of the eye due to the enveloping action. As prolongation use inert hydrophilic polymers such as water-soluble derivatives of cellulose, polyvinyl alcohol, polyethylene glycol, polyacrylamide, etc.

Eye drops, Interpan obtained as follows. Under sterile conditions receive a concentrated solution of interferon in physiological solution of sodium salts and determine its activity for further breeding to the activity specified in the claims. Subject to further dilution in physiological solution of sodium salts dissolve a portion of sgag, filtered, sterilized and aseptically mixed with a solution of interferon. The ultimate solution in terms of asepsis is poured into bottles and corked. Eye drops may contain additional carnosine, and/or a preservative, and/or the prolongator. In this case, the required number of carnosine and/or preservative, and/or prolongator is dissolved in the solution sgag. After mixing and complete dissolution of the components, the solution is filtered, sterilized, and then mixed with a solution of interferon. Total solution in terms of asepsis is poured into bottles and corked.

Example 1

Patient K. , 58 years old, diagnosed with stromal herpeticum is), aktovegin (gel), immune (internal), poludana (injection under the conjunctiva), taufona (drops), tetracycline ointment for weeks noted a slight improvement, but remained discomfort and pain in the eye, persistent epithelial defects of the cornea opacities in the corneal stroma at the third depth. Further appointed drops of Interpan of the following composition: sgag 100 µg/ml of interferon 100,000 IU/ml physiological salt solution of sodium else.

The instillation was performed 1 drop 6 times a day. On the background of treatment with Interpane in the first 2 days noted a significant improvement: the beginning of epithelialization and reduces haze allowed to cancel injection poludana. A significant effect of Interpane celebrated a week later. After 1 month there was complete resolution of turbidity and complete epithelialization.

Example 2

Patient A. , 28 years old, the diagnosis of adenoviral keratoconjunctivitis: a sharp hyperemia and edema of the mucosa of the left eye, covering transient conjunctival folds and the eyeball. On the lower eyelid of the right eye - fibrine film, corneal subepithelial point infiltrates. Along with the conventional conservative treatment was prescribed drops of Interpan 2 chapterfrom 10,000 IU/ml, carnosine 0.05%, the physiological salt solution of sodium else.

4 days after the start of treatment came signs of improvement: decreased hyperemia, disappeared discomfort. 7-8 day of the disappeared, the pain in the eyes, decreased lacrimation, decreased the number of subepithelial infiltrates. Two weeks was noted almost complete normalization condition of the mucous membranes, the cornea is barely noticeable rare subepithelial infiltrates. Assigned instillation only drops of Interpane. After another 3 days noted the disappearance of clinical signs of disease. Restore the transparency of the corneal stroma came a month after the treatment.

Example 3

Patient G. , 42 years old, diagnosed with herpetic stromal keratitis of both eyes. Appointed: instillation of Interpane - 2 drops every 30 minutes on the first day, 2 drops every 2 hours in the next 2 days, 1 drop 8 times a day, in a subsequent period the following composition: sgag 50 µg/ml of interferon 100,000 IU/ml, carnosine 0.2%, the prolongator 5%, nipagin 0,025% physiological salt solution of sodium else. At the same time appointed antibacterial therapy - instillation of chloramphenicol drops - 1 drop 6 times a day. When observed on the 2nd day was celebrated Priya conjunctiva of the eyeball. A week later, the state has been significantly improved, the eye became more calm, infiltrates in the corneal stroma decreased. Eyes completely calmed down to 16 days after the start of treatment. Restore the transparency of the cornea in both eyes came a month after the start of treatment.

Example 4

Patient M. , 55 years old, the diagnosis of adenoviral keratoconjunctivitis. Assigned instillation of chloramphenicol and Interpane of the following composition: sgag 50 µg/ml of interferon 50000 IU/ml, carnosine and 2.0%, the prolongator 0.05%, the physiological salt solution of sodium else. On the 5th day of observation noted a definite improvement: reducing photophobia, a mixed injection of the conjunctiva of the eyeball, resorption part of subepithelial haze. On the 14th day after the start of treatment eyes completely calmed down. Separate subepithelial opacities have been preserved up to 1 month, after which the cornea was completely transparent.

1. Eye drops containing glycosaminoglycans in physiological solution of sodium salts, characterized in that eye drops additionally contain interferon in the following ratio of components in 1 ml:

Glycosaminoglycans - 50 - 1000 mcg

Interferon - 10000 - 100000 IU

Fisiologicas is rat carnosine in the amount of 0,05-2,0%.

3. Eye drops for PP. 1 and 2, characterized in that they additionally contain preservative in the amount of from 0.005 to 0.03%.

4. Eye drops for PP. 1 and 3, characterized in that they additionally contain prolongator in the amount of 0.05-5%.

5. Eye drops for PP. 1-4, characterized in that as a physiological solution of sodium salts using an aqueous solution of 0.85 to 0.92% sodium chloride.

6. Eye drops for PP. 1 and 4, characterized in that as a physiological salt solution sodium use isotonic solution of sodium chloride in phosphate buffer with pH 6.8 and 7.6.

7. Eye drops for PP. 1-4, characterized in that as a physiological salt solution sodium use isotonic sodium chloride solution in borate buffer with a pH of 6.8 to 7.6.

 

Same patents:
The invention relates to medicine, namely to ophthalmology, and for the treatment of hemophthalmia

The invention relates to medicine, namely to ophthalmology, and for the treatment of degenerative diseases of the retina and optic nerve

The invention relates to medicine

The invention relates to new guanidinium heterocyclic compounds of the formula (I), where R1denotes H, alkyl or is absent when R1missing link (a) is a double bond, D represents CR2, R2selected from H, alkyl, halogen, or, when is a CR3D can be N, denotes NR9, CR3=CR8, CR3, S, where R9denotes H, alkyl, alkenyl or quinil and where R3and R8selected from H, alkyl, alkenyl, quinil or cyano, R4, R5, R6each independently selected from H, alkyl, alkenyl, quinil, cyano, halogen or NH-C(= NR10)OTHER11(guanidine), R10and R11selected from H, methyl and ethyl, and where only one of R1, R5and R6is guanidines, R7selected from H, alkyl, alkenyl, quinil and halogen

The invention relates to medicine, in particular to ophthalmology
The invention relates to medicine, namely to ophthalmology

The invention relates to medicine, namely to ophthalmology, and can be used in the treatment of retinoblastoma
The invention relates to medicine, namely to ophthalmology, and can be used for the treatment of blepharoconjunctivitis and blepharitis caused by the mite D
The invention relates to medicine, namely to Pediatrics, and can be used for the treatment of respiratory viral infections in children in the first year of life

The invention relates to medicine, therapy, can be used for the treatment of chronic viral hepatitis

The invention relates to medicine, namely to Virology, immunology, pharmacology, concerns the creation tools and development methods for increasing resistance to infection
The invention relates to medicine, in particular to neonatologie, and is intended for the treatment of respiratory distress syndrome in newborns

The invention relates to medicine, refers to a medicinal product in the form of a solution and can be used in ophthalmology, otorinolaryngology, Pediatrics and gynecology

Remedy // 2187332
The invention relates to medicine and the pharmaceutical industry and relates to dosage forms containing recombinant interferon

Drug // 2187331
The invention relates to medicine and the pharmaceutical industry and relates to encapsulated or tableted form of pharmaceutical preparations containing recombinant interferon

Antiviral agent // 2187330
The invention relates to medicine and the pharmaceutical industry and relates to formulations for the prevention and treatment of viral diseases, containing recombinant interferon

The invention relates to medicine and can be used for the prevention of sexually transmitted diseases

The invention relates to immunology and relates to the modulation of expression of TH1/TH2 cytokines and ribavirin ribavirin analogues in activated T-lymphocytes

The invention relates to veterinary
Up!